Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Natural language processing for patient selection in phase I/II oncology clinical trials

Julie Delorme, Valentin Charvet, Muriel Wartelle, François Lion, Bruno Thuillier, Sandrine Mercier, Jean-Charles Soria, Mikael Azoulay, Benjamin Besse, Christophe Massard, Antoine Hollebecque, View ORCID ProfileLoic Verlingue
doi: https://doi.org/10.1101/2021.02.07.21249271
Julie Delorme
1Institut Optique Graduate School, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentin Charvet
2Telecom Paris Tech, Paris, France
3Department of Computing Science, University of Glasgow, Glasgow G12 8RZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muriel Wartelle
4Informatic Team (DTNSI), Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Lion
4Informatic Team (DTNSI), Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Thuillier
5Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandrine Mercier
5Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Charles Soria
5Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
6University Paris-Saclay, France
7Medical Oncology Department, Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikael Azoulay
4Informatic Team (DTNSI), Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Besse
6University Paris-Saclay, France
7Medical Oncology Department, Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Massard
5Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
6University Paris-Saclay, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Hollebecque
5Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loic Verlingue
5Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
6University Paris-Saclay, France
8INSERM UMR1030, Molecular Radiotherapy and Therapeutic Innovations, Gustave Roussy, Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Loic Verlingue
  • For correspondence: loic.verlingue@gustaveroussy.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose Early discontinuation affects over one-third of patients enrolled in early-phase oncology clinical trials. Early discontinuation is deleterious both for the patient and for the study, by inflating its duration and associated costs. We aimed at predicting the successful screening and dose-limiting toxicity period completion (SSD) from automatic analysis of consultation reports.

Materials and methods We retrieved the consultation reports of patients included in phase I and/or phase II oncology trials for any tumor type at Gustave Roussy, France. We designed a pre-processing pipeline that transformed free-text into numerical vectors and gathered them into semantic clusters. These document-based semantic vectors were then fed into a machine learning model that we trained to output a binary prediction of SSD status.

Results Between September, 2012 and July, 2020, 56,924 consultation reports were used to build the dictionary, and 1,858 phase I/II inclusion reports were used to train (75%), validate (15%) and test (15%) a Random Forest model. Pre-processing could efficiently cluster words with semantic proximity. On the unseen test cohort of 264 consultation reports, the performances of the model reached: F1 score 0.80, recall 0.81 and AUC 0.88. Using this model, we could have reduced the screen fail rate (including DLT period) from 39.8% to 12.8% (RR=0.322, 95%CI[0.209-0.498], p<0.0001) within the test cohort. Most important semantic clusters for predictions comprised words related to hematological malignancies, anatomo-pathological features and laboratory and imaging interpretation.

Conclusion Machine learning with semantic conservation is a promising tool to assist physicians in selecting patients prone to achieve SSD in early-phase oncology clinical trials.

Competing Interest Statement

LV reports personal fees from Adaptherapy, non-personal fees from Pierre-Fabre and Servier, grants from Bristol-Myers Squibb, all outside the submitted work. As part of the Drug Development Department (DITEP) = Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Xencor Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Onxeo, Pfizer, Roche, Sanofi Non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Medimmune, Merck, NH TherAGuiX, Onxeo, Pfizer, Roche

Funding Statement

No funding dedicate to the study to declare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was given by the Medical Direction of Clinical Research at Gustave Roussy, represented by Pr Fabrice BARLESI and by the French Scientific Commission for Therapeutic Trials represeted by it President Pr Axel LE CESNE. Approval has been given at Villejuif, on Janurary 18th 2021, under the number : 2021-06 Opinion of the internal committee: The retrospective observational study entitled Natural language processing for patient selection in phase I/II oncology clinical trials submitted by Dr. Loic VERLINGUE has been reviewed and approved by the Scientific Commission of Gustave Roussy on 18/01/2021, which did not reveal any element contrary to medical ethics. Pr A. LE CESNE President C.S.E.T.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Our data is based on personal medical information with risk of identification. We are not allowed to publically disclose it.

https://github.com/DITEP/NLP_for_ScreenFail_prediction

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 08, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Natural language processing for patient selection in phase I/II oncology clinical trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Natural language processing for patient selection in phase I/II oncology clinical trials
Julie Delorme, Valentin Charvet, Muriel Wartelle, François Lion, Bruno Thuillier, Sandrine Mercier, Jean-Charles Soria, Mikael Azoulay, Benjamin Besse, Christophe Massard, Antoine Hollebecque, Loic Verlingue
medRxiv 2021.02.07.21249271; doi: https://doi.org/10.1101/2021.02.07.21249271
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Natural language processing for patient selection in phase I/II oncology clinical trials
Julie Delorme, Valentin Charvet, Muriel Wartelle, François Lion, Bruno Thuillier, Sandrine Mercier, Jean-Charles Soria, Mikael Azoulay, Benjamin Besse, Christophe Massard, Antoine Hollebecque, Loic Verlingue
medRxiv 2021.02.07.21249271; doi: https://doi.org/10.1101/2021.02.07.21249271

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (451)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5258)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (757)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (698)
  • Health Policy (358)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (163)
  • Infectious Diseases (except HIV/AIDS) (5867)
  • Intensive Care and Critical Care Medicine (361)
  • Medical Education (104)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (764)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (142)
  • Occupational and Environmental Health (231)
  • Oncology (479)
  • Ophthalmology (152)
  • Orthopedics (38)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (862)
  • Public and Global Health (2011)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (285)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)